Surgical Giant G Surgiwear Eyes Rs 740 Cr IPO: Is This Your Next Big Investment?

IPO
Whalesbook Logo
AuthorKavya Nair|Published at:
Surgical Giant G Surgiwear Eyes Rs 740 Cr IPO: Is This Your Next Big Investment?
Overview

Surgical products maker G Surgiwear has filed a draft document with SEBI to raise up to Rs 740 crore via Initial Public Offering (IPO). The fundraising includes Rs 370 crore from a fresh issue of shares and Rs 370 crore from promoter Ghanshyam Das Agarwal via offer-for-sale. The company plans to use proceeds for machinery purchase and debt repayment.

G Surgiwear Files for Rs 740 Crore IPO

Surgical products manufacturer G Surgiwear has submitted a draft IPO document to the Securities and Exchange Board of India (SEBI), signaling its intent to raise Rs 740 crore from the capital markets. This move aims to fuel the company's growth and strengthen its financial standing.

IPO Structure and Funding

The proposed Initial Public Offering involves a dual approach: a fresh issue of shares worth Rs 370 crore and an offer-for-sale component where promoter Ghanshyam Das Agarwal will sell shares valued at Rs 370 crore. Additionally, the company may explore a pre-IPO funding round of up to Rs 74 crore before the formal filing of the Red Herring Prospectus.

Company Evolution and Product Diversification

Founded in 1990 by Ghanshyam Das Agarwal, G Surgiwear has evolved beyond its initial focus on disposable surgical drapes and dressings. Its product portfolio now encompasses a broader range of surgical and medical implantable devices, including bone grafting products, lumbar external drainage systems, and cerebral catheter reservoirs. The company's manufacturing facility in Shahjahanpur, Uttar Pradesh, has earned international quality accreditations, including a certificate of compliance with World Health Organization - Good Manufacturing Practices (WHO-GMP).

Financial Performance and Fund Allocation

For the financial year ending March 2025, G Surgiwear reported a net profit of Rs 58 crore, a significant increase of 157.6 percent compared to the previous year. Revenue also saw a healthy rise of 32.7 percent, reaching Rs 224 crore. In the three months ended June 2025, the company recorded a profit of Rs 5.6 crore on revenue of Rs 44.6 crore. The Rs 370 crore raised from the fresh issue will be strategically allocated: Rs 167.2 crore for machinery procurement, Rs 93.6 crore for debt repayment, and the remaining amount for general corporate purposes. As of November 2025, the company's total outstanding borrowings stood at Rs 140.1 crore.

Market Positioning

G Surgiwear operates in a competitive landscape and is considered a peer to the listed company Poly Medicure. Motilal Oswal Investment Advisors and Nuvama Wealth Management have been appointed as the book running lead managers for the G Surgiwear IPO, guiding the company through the issuance process.

Impact

This IPO is expected to inject crucial capital into G Surgiwear, enabling investments in advanced machinery and significantly reducing its debt burden. This financial strengthening could position the company for enhanced operational efficiency and market expansion. For investors, the IPO represents a new opportunity within the medical devices sector, potentially offering attractive returns if the company capitalizes on its growth prospects. The success of this offering could also influence investor sentiment towards other upcoming IPOs in the healthcare and pharmaceuticals space.
Impact Rating: 7/10

Difficult Terms Explained

  • Initial Public Offering (IPO): The process by which a privately held company offers its shares to the public for the first time, allowing it to raise capital and become publicly traded.
  • SEBI (Securities and Exchange Board of India): The primary regulatory body responsible for overseeing and developing the securities market in India.
  • Red Herring Prospectus (RHP): A preliminary registration document filed by a company with regulatory authorities (like SEBI) detailing the specifics of an upcoming securities offering, which is subject to change.
  • Registrar of Companies (RoC): A government office responsible for the registration of companies and maintaining statutory records.
  • Fresh Issue: When a company issues new shares to the public to raise capital for its operations, expansion, or debt reduction.
  • Offer-for-Sale (OFS): A mechanism where existing shareholders, typically promoters or early investors, sell a portion of their stake in the company to new investors.
  • WHO-GMP (World Health Organization - Good Manufacturing Practices): A set of guidelines and standards established by the WHO to ensure that pharmaceutical and medical products are consistently produced and controlled according to quality standards.
  • Central Drugs Standard Control Organization (CDSCO): India's apex drug regulatory authority responsible for ensuring the quality, safety, and efficacy of drugs and medical devices in the country.
  • Book Running Lead Managers (BRLMs): Investment banks or financial institutions appointed to manage the process of an IPO or other public offerings, advising the issuer and underwriting the issue.
  • Outstanding Borrowings: The total amount of money that a company owes to lenders, including banks and financial institutions, which has not yet been repaid.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.